– New monotherapy and combination data in acute leukemia further highlight revumenib's compelling clinical profile – – 64% ORR (62/97) in expanded dataset of patients with R/R KMT2Ar acute leukemia in ...

FemPulse ™, a bioelectronic medical technology company with first application overactive bladder, announced today that an abstract describing the company’s two recent usability studies was selected ...

WESTON, Fla., May 28, 2024 /PRNewswire/ -- Cantex Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening ...

Late Breaking Abstract titled "Targeting SCD1 enhances activity of standard of care regorafenib in hepatocellular carcinoma: translational rationale for a phase 1/2 study of the combination of ...

Neurophet Presented Three Research Abstracts on Personalized tDCS at International Brain Stimulation Conference PR Newswire SEOUL, South Korea, Feb. 26, 2025 - Showcased core technology and products ...

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomic company committed to transforming cancer care, today announced that the company and its collaborators will present more than 15 abstracts ...

• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to ...

Please provide your email address to receive an email when new articles are posted on . Large language models may be helpful in generating scientific abstracts, according to research presented at the ...

You must submit your abstract using the online submission form. Abstracts sent by email will not be considered. Abstracts that are incomplete will not be considered. All ESA Annual Meeting proposal ...

The main theme of the Conference is to bring lessons learned from past experiences to drive future advancements in nuclear installation safety, which implies covering the wide range of nuclear safety ...